Key Takeaways
- • BNB Plus Corp. (Nasdaq: BNBX) secured initial commitments of $4.1 million in convertible preferred financing, with total proceeds expected to reach approximately $5 million, marking a capital raise tied to its strategic pivot toward digital asset treasury operations.
- • Following the financing close, the company projects cash and digital asset holdings exceeding $16.4 million as of May 23, 2026, providing liquidity to expand BNB holdings and fund a formal strategic review of capital structure and business operations.
- • The company is executing a dual-track strategy: scaling its digital asset treasury focused on the Binance ecosystem while maintaining LineaRx, its biotech subsidiary, which achieved profitability in Q2 fiscal 2026, offering operational diversification and stability.
- • Institutional digital-asset-focused investors participated in the round, including Comstock Multichain Fund (managed by Silvermine Capital Advisors) and Off the Chain, LP, signaling institutional conviction in the treasury-yield strategy targeting 9–12% annualized returns.
- • Management is conducting a broader strategic review evaluating alternatives including potential mergers, acquisitions, business combinations, and sector repositioning across both digital asset and biotechnology operations to maximize shareholder value.
Summary
BNB Plus Corp. has completed an initial close of $4.1 million in convertible preferred equity financing as part of a capital raise designed to accelerate its transformation into a digital asset treasury company. The company expects total proceeds to reach approximately $5 million, with deployment earmarked for expanding its BNB holdings, supporting working capital requirements, and funding a comprehensive strategic review of its operations and capital structure.
The financing reflects BNB Plus's repositioning from its prior identity as Applied DNA Sciences into a digitally native treasury company leveraging the Binance ecosystem. Post-close, the company projects aggregate cash and digital asset holdings of more than $16.4 million based on valuations as of May 23, 2026. This capital base positions the firm to pursue its core strategy of non-directional yield strategies targeting 9–12% annualized returns while maintaining operational flexibility.
Management has maintained BNB Plus's biotechnology operations through LineaRx, a subsidiary providing therapeutic DNA production services. Notably, LineaRx reached profitability during the second quarter of fiscal 2026, providing operational stability and diversification as the parent company evaluates strategic alternatives. Chief Executive Officer Clay Shorrock emphasized that the financing provides the capital flexibility required to pursue value-maximizing initiatives across both the digital asset and biotech segments.
The institutional investor base backing this round includes Comstock Multichain Fund, managed by Silvermine Capital Advisors, and Off the Chain, LP—both established players in digital-asset-focused investing. Their participation underscores confidence in the company's treasury-yield thesis and management's execution capability within the decentralized finance sector.
Concurrent with the financing, BNB Plus has initiated a formal review of strategic alternatives, including potential mergers, reverse mergers, business combinations, acquisitions, and sector repositioning. This dual approach—simultaneously raising capital, scaling digital asset holdings, and evaluating strategic partnerships or structural transactions—positions the company to pursue multiple pathways toward shareholder value creation in an evolving digital asset landscape.
The financing reflects BNB Plus's repositioning from its prior identity as Applied DNA Sciences into a digitally native treasury company leveraging the Binance ecosystem. Post-close, the company projects aggregate cash and digital asset holdings of more than $16.4 million based on valuations as of May 23, 2026. This capital base positions the firm to pursue its core strategy of non-directional yield strategies targeting 9–12% annualized returns while maintaining operational flexibility.
Management has maintained BNB Plus's biotechnology operations through LineaRx, a subsidiary providing therapeutic DNA production services. Notably, LineaRx reached profitability during the second quarter of fiscal 2026, providing operational stability and diversification as the parent company evaluates strategic alternatives. Chief Executive Officer Clay Shorrock emphasized that the financing provides the capital flexibility required to pursue value-maximizing initiatives across both the digital asset and biotech segments.
The institutional investor base backing this round includes Comstock Multichain Fund, managed by Silvermine Capital Advisors, and Off the Chain, LP—both established players in digital-asset-focused investing. Their participation underscores confidence in the company's treasury-yield thesis and management's execution capability within the decentralized finance sector.
Concurrent with the financing, BNB Plus has initiated a formal review of strategic alternatives, including potential mergers, reverse mergers, business combinations, acquisitions, and sector repositioning. This dual approach—simultaneously raising capital, scaling digital asset holdings, and evaluating strategic partnerships or structural transactions—positions the company to pursue multiple pathways toward shareholder value creation in an evolving digital asset landscape.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.